Ricrolin®+ is indicated in combination with UV-A emitting surgical medical device for ophthalmologic use for corneal cross-linking (CXL) of eyes with primary corneal ectasia (progressive keratoconus, pellucid marginal degeneration) or iatrogenesis.
The treatment (UV-A + riboflavin) delays the progression of keratoconus.
The treatment prevents the need for corneal transplantation.
The treatment does not exclude the possibility of a keratoplasty at a later stage.
Hypotonic Riboflavin 0.1%
1.5 mL sterile bottle
CE 0373 – Class IIb medical device
French distributor: Horus Pharma
This medical device is a regulated health product which, under this regulation, bears the CE mark.
Read the instruction leaflet carefully before use.